Jeselsohn R

ORCID: 0000-0001-7996-7529 · 2 papers in corpus

2025

Tamoxifen induces PI3K activation in uterine cancer.

Nature genetics ·doi:10.1038/s41588-025-02308-w

Mutagenic processes and clonal selection contribute to the development of therapy-associated secondary neoplasms, a known complication of cancer treatment. The association between tamoxifen therapy and secondary uterine cancers is uncommon …

2016

FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer.

Proceedings of the National Academy of Sciences of the United States of America ·doi:10.1073/pnas.1612835113

Forkhead box protein A1 (FOXA1) is a pioneer factor of estrogen receptor α (ER)-chromatin binding and function, yet its aberration in endocrine-resistant (Endo-R) breast cancer is unknown. Here, we report preclinical evidence for a role of …